BNTC:NSD-Benitec Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.07

Change

+0.33 (+8.82)%

Market Cap

USD 0.03B

Volume

4.62M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Company Website : http://www.benitec.com

Address : 3940 Trust Way, Hayward, CA, United States, 94545

Employees : 14

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 1.64

52 Week High : 7.00

Short Ratio : 1.64

52 Week Low : 2.30

Shorted Shares : 156,216

200 Day Moving Average : 4.24

Shorted Shares Previous Month : 208,368

50 Day Moving Average : 3.93

Shares Held By Insiders : 11.44%

Short Percentage : 2.00%

Shares Held by Institutions : 24.16%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+6.68 (+1.54%)

 USD175.20B 51.28 41.56
BNTX BioNTech SE

-2.09 (-0.61%)

 USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

+0.11 (+0.02%)

 USD69.19B 11.68 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.53 (-0.82%)

 USD48.20B 24.50 16.63
BGNE BeiGene Ltd

-0.33 (-0.08%)

 USD41.72B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
SGEN Seagen Inc

+4.15 (+2.51%)

 USD30.02B 51.49 39.11
GMAB Genmab A/S

-0.22 (-0.50%)

 USD28.07B 71.33 8.17
RPRX Royalty Pharma plc

-0.34 (-0.93%)

 USD22.24B 29.66 12.50
ALNY Alnylam Pharmaceuticals Inc

-1.94 (-1.05%)

 USD21.89B N/A N/A

ETFs Containing BNTC

Symbol Name Weight Mer Price(Change) Market Cap
DX2K:F Xtrackers - FTSE 100 Shor.. 0.00 % 0.50 %

-0.06 (-1.62%)

 USD0.01B
DX2K:XETRA Xtrackers FTSE 100 Short .. 0.00 % 0.50 %

-0.06 (-1.54%)

 USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.67% 80% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.67% 80% B- 80% B-
Trailing 12 Months  
Capital Gain -36.41% 21% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.41% 21% F 8% F
Trailing 5 Years  
Capital Gain 192.83% 79% C+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 192.83% 79% C+ 82% B-
Average Annual (5 Year Horizon)  
Capital Gain 105.35% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.35% 88% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 265.27% 9% F 6% F
Risk Adjusted Return 39.71% 65% D 56% F
Market Capitalization 0.03B 3% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 51.55 16% F 19% F
Price/Book Ratio 3.04 58% F 45% F
Price / Cash Flow Ratio -2.38 19% F 58% F
EV/EBITDA 0.12 75% C 95% A
Management Effectiveness  
Return on Equity -110.15% 22% F 17% F
Return on Invested Capital -0.09% 85% B 52% F
Return on Assets -58.45% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.64 76% C 69% D+
Short Percent 2.83% 72% C- 51% F
Beta 1.64 34% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector